IL126592A - Use of selective inhibitors MMP-13 for the preparation of drugs for the treatment of arthritis and other MMP-mediated disorders - Google Patents

Use of selective inhibitors MMP-13 for the preparation of drugs for the treatment of arthritis and other MMP-mediated disorders

Info

Publication number: IL126592A
Authority: IL; Israel
Prior art keywords: collagenase; mmp; benzenesulfonyl; preparation; human
Prior art date: 1997-10-24

Application number

IL12659298A

Other languages

English (en)

Hebrew (he)

Other versions

IL126592A0 (en

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-10-24

Filing date

1998-10-15

Publication date

2004-12-15

1998-10-15 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

1999-08-17 Publication of IL126592A0 publication Critical patent/IL126592A0/xx

2004-12-15 Publication of IL126592A publication Critical patent/IL126592A/en

Links

239000003814 drug Substances 0.000 title claims description 19
229940124639 Selective inhibitor Drugs 0.000 title claims description 17
238000002360 preparation method Methods 0.000 title claims description 12
201000008482 osteoarthritis Diseases 0.000 title claims description 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 8
230000001404 mediated effect Effects 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims description 41
108010076503 Matrix Metalloproteinase 13 Proteins 0.000 claims description 40
239000003112 inhibitor Substances 0.000 claims description 32
230000002401 inhibitory effect Effects 0.000 claims description 14
210000002808 connective tissue Anatomy 0.000 claims description 13
241000124008 Mammalia Species 0.000 claims description 9
150000003839 salts Chemical class 0.000 claims description 9
230000009885 systemic effect Effects 0.000 claims description 7
230000001988 toxicity Effects 0.000 claims description 7
231100000419 toxicity Toxicity 0.000 claims description 7
239000003085 diluting agent Substances 0.000 claims description 3
WNJWSNXIZOSCTK-BVRKHOPBSA-N (4-benzylphenyl)methyl-[(2s)-2-[[(2s)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]carbamoyl]-6-phenoxyhexyl]phosphinic acid Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NC)C(C)(C)C)CP(O)(=O)CC=1C=CC(CC=2C=CC=CC=2)=CC=1)CCCOC1=CC=CC=C1 WNJWSNXIZOSCTK-BVRKHOPBSA-N 0.000 claims description 2
PDFDFBYWRAAPBF-UHFFFAOYSA-N 1-[4-[(4-fluorophenyl)methoxy]phenyl]sulfonyl-2-(hydroxycarbamoyl)piperidine-4-carboxylic acid Chemical compound ONC(=O)C1CC(C(O)=O)CCN1S(=O)(=O)C(C=C1)=CC=C1OCC1=CC=C(F)C=C1 PDFDFBYWRAAPBF-UHFFFAOYSA-N 0.000 claims description 2
PZVRVCHMRVIVFR-UHFFFAOYSA-N 1-[[4-(4-fluorophenoxy)phenyl]sulfonyl-(pyridin-3-ylmethyl)amino]cyclopentane-1-carboxylic acid Chemical compound C=1C=CN=CC=1CN(S(=O)(=O)C=1C=CC(OC=2C=CC(F)=CC=2)=CC=1)C1(C(=O)O)CCCC1 PZVRVCHMRVIVFR-UHFFFAOYSA-N 0.000 claims description 2
RZJRPOXXUQVXSQ-UHFFFAOYSA-N 2-[1-[4-(4-fluorophenoxy)phenyl]sulfonylcyclobutyl]-n,2-dihydroxyacetamide Chemical compound C=1C=C(OC=2C=CC(F)=CC=2)C=CC=1S(=O)(=O)C1(C(O)C(=O)NO)CCC1 RZJRPOXXUQVXSQ-UHFFFAOYSA-N 0.000 claims description 2
RSSYAVKZTMRRBA-UHFFFAOYSA-N 2-[[4-(4-fluorophenoxy)phenyl]sulfonyl-(pyridin-3-ylmethyl)amino]-n-hydroxy-2-methylpropanamide Chemical compound C=1C=C(OC=2C=CC(F)=CC=2)C=CC=1S(=O)(=O)N(C(C)(C)C(=O)NO)CC1=CC=CN=C1 RSSYAVKZTMRRBA-UHFFFAOYSA-N 0.000 claims description 2
ANHMLPROUSINMJ-UHFFFAOYSA-N 2-amino-3-[4-(4-fluorophenoxy)phenyl]sulfonyl-n-hydroxypropanamide Chemical compound C1=CC(S(=O)(=O)CC(N)C(=O)NO)=CC=C1OC1=CC=C(F)C=C1 ANHMLPROUSINMJ-UHFFFAOYSA-N 0.000 claims description 2
WMVFDRMOZOTALK-UHFFFAOYSA-N 4-[4-(4-chlorophenyl)phenyl]-2-[2-(1,3-dioxoisoindol-2-yl)ethyl]-4-oxobutanoic acid Chemical compound O=C1C2=CC=CC=C2C(=O)N1CCC(C(=O)O)CC(=O)C(C=C1)=CC=C1C1=CC=C(Cl)C=C1 WMVFDRMOZOTALK-UHFFFAOYSA-N 0.000 claims description 2
102000017284 Collagenase 3 Human genes 0.000 claims 13
ILUHDZNQHNLNDX-UHFFFAOYSA-N 3-[4-(4-fluorophenoxy)phenyl]sulfonyl-n,2-dihydroxypropanamide Chemical compound C1=CC(S(=O)(=O)CC(O)C(=O)NO)=CC=C1OC1=CC=C(F)C=C1 ILUHDZNQHNLNDX-UHFFFAOYSA-N 0.000 claims 1
ROSNVSQTEGHUKU-UHFFFAOYSA-N 4-[4-(4-chloro-phenoxy)-benzenesulfonylmethyl]-tetrahydro-pyran-4-carboxylic acid hydroxyamide Chemical compound C=1C=C(OC=2C=CC(Cl)=CC=2)C=CC=1S(=O)(=O)CC1(C(=O)NO)CCOCC1 ROSNVSQTEGHUKU-UHFFFAOYSA-N 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
ZRHASEWAGMDDQP-UHFFFAOYSA-N n-hydroxy-2-[(4-phenoxyphenyl)sulfonyl-(pyridin-3-ylmethyl)amino]acetamide Chemical compound C=1C=C(OC=2C=CC=CC=2)C=CC=1S(=O)(=O)N(CC(=O)NO)CC1=CC=CN=C1 ZRHASEWAGMDDQP-UHFFFAOYSA-N 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
102100027995 Collagenase 3 Human genes 0.000 description 65
108050005238 Collagenase 3 Proteins 0.000 description 40
102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 39
108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 39
210000000845 cartilage Anatomy 0.000 description 36
102000029816 Collagenase Human genes 0.000 description 33
108060005980 Collagenase Proteins 0.000 description 33
238000003556 assay Methods 0.000 description 23
229960002424 collagenase Drugs 0.000 description 23
230000005764 inhibitory process Effects 0.000 description 23
230000000694 effects Effects 0.000 description 20
229920001436 collagen Polymers 0.000 description 19
102000008186 Collagen Human genes 0.000 description 18
108010035532 Collagen Proteins 0.000 description 18
102000004190 Enzymes Human genes 0.000 description 18
108090000790 Enzymes Proteins 0.000 description 18
102000000589 Interleukin-1 Human genes 0.000 description 18
108010002352 Interleukin-1 Proteins 0.000 description 18
229940088598 enzyme Drugs 0.000 description 18
102000002274 Matrix Metalloproteinases Human genes 0.000 description 16
108010000684 Matrix Metalloproteinases Proteins 0.000 description 16
230000011382 collagen catabolic process Effects 0.000 description 16
101150014058 MMP1 gene Proteins 0.000 description 13
108700004333 collagenase 1 Proteins 0.000 description 13
239000000758 substrate Substances 0.000 description 12
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
239000003636 conditioned culture medium Substances 0.000 description 11
210000001519 tissue Anatomy 0.000 description 11
102000004142 Trypsin Human genes 0.000 description 10
108090000631 Trypsin Proteins 0.000 description 10
239000012588 trypsin Substances 0.000 description 10
229940079593 drug Drugs 0.000 description 9
238000002474 experimental method Methods 0.000 description 9
102000000503 Collagen Type II Human genes 0.000 description 8
108010041390 Collagen Type II Proteins 0.000 description 8
239000000243 solution Substances 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 7
239000002442 collagenase inhibitor Substances 0.000 description 7
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
238000000034 method Methods 0.000 description 6
NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical class C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 5
241000283690 Bos taurus Species 0.000 description 5
238000003271 compound fluorescence assay Methods 0.000 description 5
239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 5
229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 5
210000002184 nasal cartilage Anatomy 0.000 description 5
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
210000001188 articular cartilage Anatomy 0.000 description 4
239000012895 dilution Substances 0.000 description 4
238000010790 dilution Methods 0.000 description 4
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 4
229960002591 hydroxyproline Drugs 0.000 description 4
239000002609 medium Substances 0.000 description 4
239000002953 phosphate buffered saline Substances 0.000 description 4
230000000638 stimulation Effects 0.000 description 4
239000011550 stock solution Substances 0.000 description 4
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 4
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
102000012422 Collagen Type I Human genes 0.000 description 3
108010022452 Collagen Type I Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
102100030411 Neutrophil collagenase Human genes 0.000 description 3
101710118230 Neutrophil collagenase Proteins 0.000 description 3
108030001564 Neutrophil collagenases Proteins 0.000 description 3
102000056189 Neutrophil collagenases Human genes 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
239000012131 assay buffer Substances 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000011534 incubation Methods 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
239000000203 mixture Substances 0.000 description 3
230000003349 osteoarthritic effect Effects 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
238000012360 testing method Methods 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
-1 (4-benzyl-benzyl)-{2-[2-(4-methoxy-phenyl)-1-methylcarbamoyl-ethylcarbamoyl]-6-phenoxy-hexyl}-phosphinic acid 3- [4-(4-fluorophenoxy)benzenesulfonyl]-2,N-dihydroxy-propionamide Chemical compound 0.000 description 2
IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 2
NCQJBPXXRXOIJD-UHFFFAOYSA-N 3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-naphthalen-2-ylpropanoic acid Chemical compound C1=CC=CC2=CC(C(CC(O)=O)NC(=O)OC(C)(C)C)=CC=C21 NCQJBPXXRXOIJD-UHFFFAOYSA-N 0.000 description 2
102100036601 Aggrecan core protein Human genes 0.000 description 2
108010067219 Aggrecans Proteins 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
208000012659 Joint disease Diseases 0.000 description 2
229940124761 MMP inhibitor Drugs 0.000 description 2
239000004365 Protease Substances 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
230000000593 degrading effect Effects 0.000 description 2
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
230000005284 excitation Effects 0.000 description 2
210000004195 gingiva Anatomy 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000008101 lactose Substances 0.000 description 2
210000003041 ligament Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000005499 meniscus Effects 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
239000006199 nebulizer Substances 0.000 description 2
239000013642 negative control Substances 0.000 description 2
239000013641 positive control Substances 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
239000007921 spray Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
210000002435 tendon Anatomy 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
QCOQJYRPDUMCNP-UHFFFAOYSA-N 2-[[4-(4-fluorophenoxy)phenyl]sulfonylamino]-n-hydroxy-2-methylpropanamide Chemical compound C1=CC(S(=O)(=O)NC(C)(C)C(=O)NO)=CC=C1OC1=CC=C(F)C=C1 QCOQJYRPDUMCNP-UHFFFAOYSA-N 0.000 description 1
108091007504 ADAM10 Proteins 0.000 description 1
108091007507 ADAM12 Proteins 0.000 description 1
108091005660 ADAMTS1 Proteins 0.000 description 1
102000051388 ADAMTS1 Human genes 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
206010007710 Cartilage injury Diseases 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
102100039673 Disintegrin and metalloproteinase domain-containing protein 10 Human genes 0.000 description 1
102100031112 Disintegrin and metalloproteinase domain-containing protein 12 Human genes 0.000 description 1
102100031111 Disintegrin and metalloproteinase domain-containing protein 17 Human genes 0.000 description 1
241000792859 Enema Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000777461 Homo sapiens Disintegrin and metalloproteinase domain-containing protein 17 Proteins 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
102000055008 Matrilin Proteins Human genes 0.000 description 1
108010072582 Matrilin Proteins Proteins 0.000 description 1
102000005741 Metalloproteases Human genes 0.000 description 1
108010006035 Metalloproteases Proteins 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000016611 Proteoglycans Human genes 0.000 description 1
108010067787 Proteoglycans Proteins 0.000 description 1
241000219061 Rheum Species 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229940122618 Trypsin inhibitor Drugs 0.000 description 1
101710162629 Trypsin inhibitor Proteins 0.000 description 1
239000013543 active substance Substances 0.000 description 1
108010003059 aggrecanase Proteins 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
235000010290 biphenyl Nutrition 0.000 description 1
230000037396 body weight Effects 0.000 description 1
201000008275 breast carcinoma Diseases 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
229960003563 calcium carbonate Drugs 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
229960004424 carbon dioxide Drugs 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 1
210000001612 chondrocyte Anatomy 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
230000036569 collagen breakdown Effects 0.000 description 1
238000004040 coloring Methods 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
229940042935 dichlorodifluoromethane Drugs 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
201000010099 disease Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000001879 gelation Methods 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229960002449 glycine Drugs 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
230000008407 joint function Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
229950008959 marimastat Drugs 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
SZKMCHLPUYMUBI-UHFFFAOYSA-N n-hydroxy-2-[(4-phenylmethoxyphenyl)sulfonyl-(pyridin-3-ylmethyl)amino]acetamide Chemical compound C=1C=C(OCC=2C=CC=CC=2)C=CC=1S(=O)(=O)N(CC(=O)NO)CC1=CC=CN=C1 SZKMCHLPUYMUBI-UHFFFAOYSA-N 0.000 description 1
CFMZNOSRPLVMIK-UHFFFAOYSA-N n-hydroxy-3-(4-phenoxyphenyl)sulfonyl-7-oxabicyclo[2.2.1]heptane-2-carboxamide Chemical compound ONC(=O)C1C(O2)CCC2C1S(=O)(=O)C(C=C1)=CC=C1OC1=CC=CC=C1 CFMZNOSRPLVMIK-UHFFFAOYSA-N 0.000 description 1
239000006225 natural substrate Substances 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
RCCYSVYHULFYHE-UHFFFAOYSA-N pentanediamide Chemical class NC(=O)CCCC(N)=O RCCYSVYHULFYHE-UHFFFAOYSA-N 0.000 description 1
238000003359 percent control normalization Methods 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000002265 prevention Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
239000003380 propellant Substances 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229960001790 sodium citrate Drugs 0.000 description 1
235000011083 sodium citrates Nutrition 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
210000001258 synovial membrane Anatomy 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
230000007306 turnover Effects 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000011592 zinc chloride Substances 0.000 description 1
235000005074 zinc chloride Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IL12659298A 1997-10-24 1998-10-15 Use of selective inhibitors MMP-13 for the preparation of drugs for the treatment of arthritis and other MMP-mediated disorders IL126592A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US6276697P	1997-10-24	1997-10-24

Publications (2)

Publication Number	Publication Date
IL126592A0 IL126592A0 (en)	1999-08-17
IL126592A true IL126592A (en)	2004-12-15

Family

ID=22044655

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL12659298A IL126592A (en)	1997-10-24	1998-10-15	Use of selective inhibitors MMP-13 for the preparation of drugs for the treatment of arthritis and other MMP-mediated disorders

Country Status (11)

Country	Link
EP (1)	EP0935963A3 (de)
JP (1)	JPH11199512A (de)
KR (1)	KR19990037347A (de)
AU (1)	AU758147B2 (de)
CA (1)	CA2251197C (de)
HU (1)	HUP9802464A3 (de)
IL (1)	IL126592A (de)
MY (1)	MY129293A (de)
NZ (1)	NZ332478A (de)
TW (1)	TW541176B (de)
ZA (1)	ZA989667B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ336836A (en) *	1997-02-11	2001-02-23	Pfizer	Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments
CN1213021C (zh) *	1998-02-19	2005-08-03	惠氏控股公司	作为基质金属蛋白酶抑制剂的 n －羟基－ 2 － (烷基、芳基或杂芳基硫烷基、亚磺酰基或磺酰基 ) － 3 －取代的烷
US6506936B1 (en) *	1999-02-25	2003-01-14	Fibrogen, Inc.	N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of c-proteinase and for treating or preventing disorders related to unregulated collagen production
AU3196200A (en) *	1999-03-26	2000-10-16	Shionogi & Co., Ltd.	Beta-amino acid derivatives
CA2400243A1 (en) *	2000-02-10	2001-08-16	Ono Pharmaceutical Co., Ltd.	A treatment agent for osteoarthritis
US6458822B2 (en)	2000-03-13	2002-10-01	Pfizer Inc.	2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
WO2001070696A1 (en) *	2000-03-21	2001-09-27	Ishihara Sangyo Kaisha, Ltd.	Nitroethenamine derivatives or salts thereof and pharmaceutical compositions containing the derivatives or the salts
KR100365926B1 (ko)	2001-01-04	2002-12-26	삼성전자 주식회사	휴대용 전자기기의 보조전원공급장치
PA8539501A1 (es)	2001-02-14	2002-09-30	Warner Lambert Co	Compuestos triazolo como inhibidores de mmp
MXPA03005870A (es)	2001-02-14	2005-02-14	Warner Lambert Co	Inhibirores de benzotiadiazina de metaloproteinasas de la matriz.
DOP2002000333A (es)	2001-02-14	2002-09-30	Warner Lambert Co	Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
DOP2002000332A (es)	2001-02-14	2002-08-30	Warner Lambert Co	Inhibidores de piridina de metaloproteinasas de la matriz
JP2004518723A (ja)	2001-02-14	2004-06-24	ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー	ピリミジンマトリックスメタロプロテイナーゼ阻害剤
JPWO2003013494A1 (ja) *	2001-08-06	2004-11-25	小野薬品工業株式会社	変形性関節症治療剤
US6924276B2 (en)	2001-09-10	2005-08-02	Warner-Lambert Company	Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
MXPA04002537A (es)	2001-10-12	2004-05-31	Warner Lambert Co	Alquinos como inhibidores de metaloproteinasa de matriz.
US6962922B2 (en)	2001-10-12	2005-11-08	Warner-Lambert Company Llc	Alkynylated quinazoline compounds
US6894057B2 (en)	2002-03-08	2005-05-17	Warner-Lambert Company	Oxo-azabicyclic compounds
TW200305396A (en) *	2002-03-27	2003-11-01	Shionogi & Co	Cartilage extracellular matrix degradation
EP1531904A1 (de) *	2002-07-17	2005-05-25	Warner-Lambert Company LLC	Pharmazeutische zusammensetzung enthaltend einen allosterischen matrix-metalloproteinase-13-inhibitor sowie einen cyclooxygenase-2-inhibitor der nicht celecoxib oder valdecoxib ist
BR0312727A (pt) *	2002-07-17	2005-04-19	Warner Lambert Co	Combinação de um inibidor alostérico da metaloproteinase-13 de matriz com celecoxib ou valdecoxib
AU2003250470A1 (en)	2002-08-13	2004-02-25	Warner-Lambert Company Llc	Pyrimidinone fused bicyclic metalloproteinase inhibitors
MXPA05001603A (es)	2002-08-13	2005-04-25	Warner Lambert Co	Derivados monociclicos como inhibidores de metaloproteinasa de matriz.
MXPA05001783A (es)	2002-08-13	2005-04-25	Warner Lambert Co	Derivados de pirimidina-2,4-diona como inhibidores de las metaloproteinasas de matriz.
AU2003253186A1 (en)	2002-08-13	2004-02-25	Warner-Lambert Company Llc	Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
WO2004014378A1 (en)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
CA2497658A1 (en)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Chromone derivatives as matrix metalloproteinase inhibitors
PA8578101A1 (es)	2002-08-13	2004-05-07	Warner Lambert Co	Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
WO2004014375A2 (en)	2002-08-13	2004-02-19	Warner-Lambert Company Llc	Fused bicyclic metalloproteinase inhibitors
MXPA05001786A (es)	2002-08-13	2005-04-25	Warner Lambert Co	Derivados de azaisoquinolina como inhibidores de la metaloproteinasa de matriz.
AU2003249477A1 (en)	2002-08-13	2004-02-25	Warner-Lambert Company Llc	Heterobicylcic metalloproteinase inhibitors
ITFI20040174A1 (it) *	2004-08-03	2004-11-03	Protera S R L	Derivati arilsolfonammidici dell'acido idrossammico ad azione inibitoria di metalloproteinasi
WO2012048291A2 (en)	2010-10-08	2012-04-12	Proteapex Therapeutics Llc	Compositions and methods for inhibition of mmp:mmp-substrate interactions
TWI480057B (zh)	2013-07-08	2015-04-11	Univ China Medical	咖啡酸醯胺衍生物之應用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5768417A (en) *	1994-09-09	1998-06-16	Motorola, Inc.	Method and system for velocity-based handwriting recognition
DE19501032A1 (de) *	1995-01-14	1996-07-18	Max Delbrueck Centrum	Mittel zur Behandlung von rheumatischen Erkrankungen
EA003294B1 (ru) *	1995-12-08	2003-04-24	Агурон Фармасьютикалс, Инк.	Ингибиторы металлопротеиназы, фармацевтические композиции, их содержащие, и их фармацевтические применения
DK0780386T3 (da) *	1995-12-20	2003-02-03	Hoffmann La Roche	Matrixmetalloproteaseinhibitorer

1998
- 1998-10-12 JP JP10289540A patent/JPH11199512A/ja active Pending
- 1998-10-15 IL IL12659298A patent/IL126592A/en not_active IP Right Cessation
- 1998-10-20 EP EP98308563A patent/EP0935963A3/de not_active Withdrawn
- 1998-10-22 CA CA002251197A patent/CA2251197C/en not_active Expired - Fee Related
- 1998-10-22 MY MYPI98004820A patent/MY129293A/en unknown
- 1998-10-22 AU AU89481/98A patent/AU758147B2/en not_active Ceased
- 1998-10-22 HU HU9802464A patent/HUP9802464A3/hu unknown
- 1998-10-23 ZA ZA9809667A patent/ZA989667B/xx unknown
- 1998-10-23 KR KR1019980044595A patent/KR19990037347A/ko not_active Ceased
- 1998-10-23 TW TW087117632A patent/TW541176B/zh not_active IP Right Cessation
- 1998-10-23 NZ NZ332478A patent/NZ332478A/xx unknown

Also Published As

Publication number	Publication date
EP0935963A3 (de)	2000-10-04
IL126592A0 (en)	1999-08-17
TW541176B (en)	2003-07-11
KR19990037347A (ko)	1999-05-25
AU8948198A (en)	1999-05-20
AU758147B2 (en)	2003-03-13
CA2251197A1 (en)	1999-04-24
NZ332478A (en)	2000-07-28
ZA989667B (en)	2000-04-25
CA2251197C (en)	2004-07-27
JPH11199512A (ja)	1999-07-27
HUP9802464A2 (hu)	1999-08-30
MY129293A (en)	2007-03-30
EP0935963A2 (de)	1999-08-18
HUP9802464A3 (en)	2001-04-28
HU9802464D0 (en)	1998-12-28

Legal Events

Date	Code	Title
2005-05-17	FF	Patent granted
2005-07-25	KB	Patent renewed
2009-12-24	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
CA2251197C (en)	2004-07-27	The use of mmp-13 selective inhibitors for the treatment of osteoarthritis and other mmp-mediated disorders
US6417229B1 (en)	2002-07-09	α-sulfonylamino hydroxamic acid inhibitors of matrix metalloproteinases for the treatment of peripheral or central nervous system disorders
AU770798B2 (en)	2004-03-04	The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
AU761585B2 (en)	2003-06-05	The use of MMP inhibitors for the treatment of ocular angiogenesis
JP4130179B2 (ja)	2008-08-06	骨髄腫を処置するためのｃ−ｋｉｔ阻害剤の使用
EP0946166B1 (de)	2004-02-18	Verwendung von matrix-metalloproteinase inhibitoren zur förderung der wundheilung
JP2002525294A (ja)	2002-08-13	ビスホスホネート及びテトラサイクリンの組合せ
JP2008544988A (ja)	2008-12-11	眼細胞におけるゼラチナーゼａ活性を増大するための、カルボニル部分で置換されたアリールアジンを含む製剤
EP1542687B1 (de)	2009-01-28	Kleine organische moleküle, die die aktivität von gelatinase a in zellen der augen steigern
KR930010581B1 (ko)	1993-10-30	콜라게나제의 활성화를 저해하기 위한 테니댑(Tenidap)의 용도
OTSUKA et al.	1999	WF14861, a new cathepsins B and L inhibitor produced by Colletotrichum sp. II. Biological properties
JP4187141B2 (ja)	2008-11-26	新規なトロンボモジュリン発現促進剤
JP4643887B2 (ja)	2011-03-02	医療的に価値のある活性成分の検出方法
KR100541536B1 (ko)	2006-06-21	노르디히드로구아이아레트산과 인도메타신을 함유하는 경골 또는 결체조직 재생용 약학적 조성물
WO2023172594A2 (en)	2023-09-14	Method for treating rheumatoid arthritis (ra) using an enzyme-and substrate selective exosite inhibitor of a disintegrin and metalloprotease 10 (adam10)
Jüngel et al.	2009	Therapeutic modulation of invasive behaviour of synovial fibroblast in rheumatoid arthritis
CA2276013A1 (en)	1999-05-14	The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
US20140213781A1 (en)	2014-07-31	Cyclic tripeptide mimetics as plasmin inhibitors